Castle Biosciences Inc. (CSTL) Tops Q4 EPS by 48c ; Offers Guidance

Castle Biosciences Inc. (NASDAQ: CSTL) reported Q4 EPS of ($0.10), $0.48 better than the analyst estimate of ($0.58). Revenue for the quarter came in at $66.12 million versus the consensus estimate of $55.02 million.

GUIDANCE:

Castle Biosciences Inc. sees FY2024 revenue of $235-240 million, versus the consensus of $214.7 million.

For earnings history and earnings-related data on Castle Biosciences Inc. (CSTL) click here.

You May Also Be Interested In

• Forum Markets, Incorporated (FRMM) Tops Q2 EPS by 29c ; Offers Guidance
• McGraw Hill (MH) Tops Q2 EPS by 11c, Beats on Revenue; Offers FY26 Guidance
• Ondas Holdings Inc. (ONDS) Misses Q2 EPS by 9c